BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more
BrightGene Bio Medical Technology C - Asset Resilience Ratio
BrightGene Bio Medical Technology C (688166) has an Asset Resilience Ratio of 1.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how BrightGene Bio Medical Technology C's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BrightGene Bio Medical Technology C's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥51.01 Million | 1.0% |
| Total Liquid Assets | CN¥51.01 Million | 1.00% |
Asset Resilience Insights
- Limited Liquidity: BrightGene Bio Medical Technology C maintains only 1.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BrightGene Bio Medical Technology C Industry Peers by Asset Resilience Ratio
Compare BrightGene Bio Medical Technology C's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for BrightGene Bio Medical Technology C (2016–2023)
The table below shows the annual Asset Resilience Ratio data for BrightGene Bio Medical Technology C.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.01% | CN¥50.62 Million | CN¥5.03 Billion | -0.07pp |
| 2022-12-31 | 1.08% | CN¥50.12 Million | CN¥4.66 Billion | +1.05pp |
| 2021-12-31 | 0.03% | CN¥763.45K | CN¥2.97 Billion | -9.82pp |
| 2020-12-31 | 9.85% | CN¥180.04 Million | CN¥1.83 Billion | +9.53pp |
| 2016-12-31 | 0.32% | CN¥1.21 Million | CN¥384.19 Million | -- |